Older adults and even younger individuals in their early 20s can experience androgenetic alopecia, a genetic condition that can affect both genders. In men, it’s known as male pattern baldness and is characterized by a receding hairline from the crown and frontal scalp. In women, the condition is called female pattern baldness and is characterized by extensive hair loss at the crown.
A study by Vickers and colleagues investigated the safety and efficacy of the metallopeptide (amino acid that contains metal ion) zinc-thymulin for treating androgenetic alopecia.  In this study, 18 adult subjects (17 males and 1 female) with age range of 35-90 years and with a diagnosis of androgenetic alopecia were included. All subjects received topical spray of zinc-thymulin to the scalp for 4-10 months. Baseline and after treatment images of the scalp were taken in order to determine improvement in hair growth.
After 3,300 treatment days, zinc-thymulin produced no adverse effects or local side effects. Significant hair assessment improvement was observed in subjects who completed 6 months or more of continuous treatment. This was evidenced by a significant increase in the number of new hair growths, unlike in baseline where absent hair was noticeable in some regions of the scalp.
These findings suggest that topical applications of zinc-thymulin for 6 months or more is safe and effective for initiating and maintaining the anagen phase of hair cycle, making it a potential therapeutic option for male and female pattern baldness.
Call 800-277-4041 for a Free Consultation
Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.